AnaptysBio to Participate in Upcoming November Investor Conferences
10 November 2022 - 6:10AM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company focused on delivering innovative immunology therapeutics,
today announced that Dan Faga, chief executive officer of
AnaptysBio, will represent the company in a fireside chat at the
Guggenheim 4th Annual Immunology and Neurology Conference on Monday
November 14th, 2022, at 1:00 p.m. ET / 10:00 a.m. PT; members of
its senior management team will also be hosting investor meetings
at the Jefferies London Healthcare Conference on November 16th,
2022.
A live audio webcast of the presentation will be available on
the investor section of the AnaptysBio website at
https://ir.anaptysbio.com/events. A replay of the
webcast will be available for 30 days following the event.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company focused on
delivering innovative immunology therapeutics. We are developing
immune cell modulators, including two checkpoint agonists in
clinical-stage development, for autoimmune and inflammatory
disease: rosnilimab, our anti-PD-1 agonist program in Phase 2 for
the treatment of moderate-to-severe alopecia areata; and ANB032,
our anti-BTLA agonist program. AnaptysBio is also developing
imsidolimab, our anti-IL-36R antibody in Phase 3 for the treatment
of generalized pustular psoriasis, or GPP. We also have additional
preclinical programs and discovery research of potentially
innovative immunology therapeutics, including ANB033,
an anti-CD122 antagonist antibody for the treatment of
inflammatory diseases. AnaptysBio has also developed multiple
therapeutic antibodies in an immuno-oncology collaboration with
GSK, including an anti-PD-1 antagonist antibody (JEMPERLI
(dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab,
GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386).
Contact:Dennis MulroyAnaptysBio,
Inc.858.732.0201dmulroy@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Apr 2023 to Apr 2024